INTRODUCTION
============

Chronic kidney disease (CKD) is increasingly recognized as a major global health problem. CKD has been identified as a risk factor for premature death ([@B1],[@B2]) and as a predictor of worse quality of life ([@B3],[@B4]). The World Health Organization Global Burden of Disease measures the overall burden of disease using the disability-adjusted life year ([@B5]). This time-based measure combines years of life lost due to premature mortality and years of life lost due to time lived in states of less-than-full health. In the 2010 Global Burden of Disease Study, CKD was ranked as the 17th cause of disability-adjusted life year in the United States ([@B6]). Measuring the burden of disease provides a critical resource for evidence-informed health policy-making. Precise estimates of the prevalence as well as the disability weight and mortality are required to reliably quantify the cause-specific disability-adjusted life year.

A high prevalence of CKD has been reported in a number of population-based studies from different countries. The overall prevalence of CKD among 13,233 non-institutionalized adults aged ≥ 20 years in the United States was 13.1% ([@B7]). A recent study performed in China reported that the prevalence of CKD among 47,204 adults aged ≥ 18 years was 10.8% ([@B8]). The growing elderly population and increasing rate of diabetes mellitus and hypertension may contribute to the high prevalence of CKD worldwide. The prevalence of CKD in Korea has been reported as 13.7% among 2,356 urban civilians aged ≥ 35 years ([@B9]).

CKD is defined based on markers of kidney damage (most often albuminuria) and a decreased glomerular filtration rate (GFR). Most population-based studies to date have defined CKD based on the estimated glomerular filtration rate (eGFR) using the Modification of Diet in Renal Disease Study (MDRD) equation. However, the 2012 Kidney Disease: Improving Global Outcomes (KDIGO) guidelines, which was an update from the original 2002 Kidney Disease Outcomes Quality Initiative guidelines, recommends the CKD-Epidemiology Collaboration (CKD-EPI) creatinine equation for estimating GFR using creatinine assays with calibration traceable to standardized reference material ([@B10]).

The Korean National Health and Nutrition Examination Survey (KNHANES) may provide a basis for estimating CKD prevalence in the general population. This large, nationwide, representative survey conducted by the Korea Centers for Disease Control and Prevention (KCDC) includes laboratory examinations of urine albumin concentrations and serum creatinine levels standardized to isotope dilution mass spectrometry (IDMS), allowing for the identification and classification of CKD. The purpose of the present study was to provide nationally representative, population-based prevalence estimates of CKD among Korean adults in clinically relevant subpopulations from the KNHANES data.

MATERIALS AND METHODS
=====================

Subjects
--------

The KNHANES is a population-based, cross-sectional study on the health and nutritional status of the non-institutionalized Korean population. The KCDC conducted the survey using a stratified, multistage, clustered probability design to select a representative, nationwide sample. The KNHANES comprises a health questionnaire, physical/laboratory examinations, and a nutrition survey; to date, phase I (1998), II (2001), III (2005), IV (2007--2009), V (2010--2012), and VI (2013--2015) surveys have been conducted. The present study was based on the data obtained from KNHANES in 2011--2013 because urine albumin concentrations were measured since 2011, and complete data from KNHANES 2014--2015 had not yet been released when these analyses were conducted.

Of the 23,280 subjects participating in KNHANES 2011--2013, we excluded subjects younger than 20 years (n = 5,460) and adults in whom serum creatinine levels or urine albumin/creatinine concentrations were not measured (n = 2,494). After these exclusions, 15,319 subjects (6,891 men and 8,428 women) were included in the final analysis.

Anthropometric and laboratory data
----------------------------------

Trained medical staff performed the physical examinations following standardized procedures. Subjects' body weight and height were measured to the nearest 0.1 kg and 0.1 cm, respectively, with subjects wearing light indoor clothing without shoes. Blood pressure was measured manually three times at 30-seconds intervals after a minimum of 5 minutes of rest in a seated position, and recorded as an average value of the second and third measurements.

Blood samples were collected after at least an 8-hour fast, and random spot urine samples were obtained from the subjects. The samples were properly processed, immediately refrigerated, and transported in cold storage to the central laboratory within 24 hours. Serum and urine creatinine concentrations were measured by the colorimetric method using the Hitachi Automatic Analyzer 7600 (Hitachi, Tokyo, Japan) in KNHANES 2011 and 2012, and by the Jaffe rate-blanked and compensated method using the COBAS 8000 C702 (Roche, Mannheim, Germany) in KNHANES 2013. Serum glucose concentrations were measured by the enzymatic method. Urinary albumin concentrations were measured by the turbidimetric immunoassay using the Hitachi Automatic Analyzer 7600 (Hitachi).

Kidney function
---------------

The eGFR was calculated from the serum creatinine level standardized to IDMS using the CKD-EPI creatinine equation ([@B11]). The urine albumin-to-creatinine ratio (ACR) was calculated in mg of albumin per g of creatinine (mg/g). We used five eGFR categories (G1, eGFR ≥ 90 mL/min/1.73 m^2^; G2, eGFR 60--89 mL/min/1.73 m^2^; G3a, eGFR 45--59 mL/min/1.73 m^2^; G3b, eGFR 30--44 mL/min/1.73 m^2^; G4-5, eGFR \< 30 mL/min/1.73 m^2^) and three albuminuria categories (A1, ACR \< 30 mg/g; A2, ACR 30--300 mg/g; A3, ACR \> 300 mg/g) according to the KDIGO staging system ([@B10]).

We ascertained kidney damage as an ACR ≥ 30 mg/g and a decreased GFR as an eGFR \< 60 mL/min/1.73 m^2^. Hence, CKD was defined as an ACR ≥ 30 mg/g or an eGFR \< 60 mL/min/1.73 m^2^. In populations with CKD, the eGFR and albuminuria categories were grouped with similar relative risk for adverse outcomes into three risk categories: moderately increased risk, G3a-A1 or G1-2A2; high risk, G3b-A1, G3a-A2, or G1-2A3; very high risk, G4-5A1, G3b-5A2, or G3a-5A3 ([@B10]). We also classified CKD according to the conventional staging system: stage 1, G1-A2--3; stage 2, G2-A2--3; stage 3a, G3a-A1--3; stage 3b, G3b-A1--3; and stages 4--5, G4--5-A1--3.

Demographic and clinical characteristics
----------------------------------------

The analyzed sociodemographic characteristics included age, sex, education level (middle school or lower/high school or higher), household income (the lower fourth/three higher fourths) and residential area (rural/urban). Smoking was dichotomized as current or former smokers/nonsmokers. Diabetes mellitus was defined as a serum fasting glucose level ≥ 126 mg/dL, use of anti-diabetic medicine, or a physician diagnosis of diabetes mellitus. Hypertension was defined as systolic blood pressure ≥ 140 mmHg, diastolic blood pressure ≥ 90 mmHg, or the use of blood pressure-lowering medication. We defined cardiovascular disease as self-reported, physician-diagnosed angina pectoris, acute myocardial infarction, or stroke.

Statistical analysis
--------------------

Statistical analyses were performed with SPSS (version 22.0; SPSS Inc., Chicago, IL, USA). For the KNHANES, the KCDC used a complex sample design (stratification, clustering, and unequal selection probabilities). Therefore, SPSS Complex Samples module was used to obtain valid point estimates and confidence intervals, and test our hypothesis.

The composite sample weight was introduced into our analyses to provide representative estimates of the non-institutionalized Korean population. We calculated the composite weight by multiplying the survey weight by one-third for each of the years (2011--2013). The survey weight for subjects participating in the health questionnaire and physical/laboratory examinations was calculated using the sampling rate, response rate, and age/sex proportion of the Korean population. The SPSS Complex Samples module computed correct confidence intervals and significance tests by the Taylor series method, which incorporated the sample weight, stratum, and primary sampling unit.

Logistic regression analysis was used to evaluate the odds ratios for CKD by independent variables. The group without each corresponding characteristic served as the reference, and the group with a body mass index (BMI) of 18.5−24.9 kg/m^2^ served as the reference BMI category.

Ethics statement
----------------

KNHANES phases V and VI were approved by the institutional review board of the KCDC (IRB No. 2011-02CON-06-C, 2012-01EXP-01-2C, and 2013-07CON-03-4C). The need for informed consent was waived by the board.

RESULTS
=======

Subjects' characteristics
-------------------------

The demographic characteristics of the study sample, weighted to be representative of the Korean population, were as follows; the mean age was 46.1 years, and 47.2% were women. The mean eGFR was 95.9 mL/min/1.73 m^2^, and the mean ACR was 18.3 mg/g. The prevalence of diabetes mellitus, hypertension, and diagnosed cardiovascular disease were 9.2%, 26.7%, and 3.2%, respectively.

Classification by eGFR and albuminuria categories
-------------------------------------------------

The proportions of categories classified based on eGFR and albuminuria are shown in [Table 1](#T1){ref-type="table"}. The total prevalence estimate of albuminuria with an ACR ≥ 30 mg/g was 6.7%: ACR 30--300 mg/g, 5.8% and ACR \> 300 mg/g, 0.9%. The total prevalence estimate of a decreased GFR with an eGFR \< 60 mL/min/1.73 m^2^ was 2.5%: G3a, 1.9%; G3b, 0.4%; and G4--5, 0.2%. The prevalence of albuminuria and a decreased GFR were higher in the populations with older age, diabetes, hypertension, and diagnosed cardiovascular disease compared to the general population.

###### Populations by eGFR and albuminuria categories: complex samples analysis (Korean National Health and Nutrition Examination Survey, 2011−2013 \[study sample n = 15,319\])

![](jkms-31-915-i001)

  -------------------------------------------------------------------------------------------------------------------------------------------------
  eGFR categories:\                                    Albuminuria categories: ACR, mg/g   Total                                
  eGFR, mL/min/1.73 m^2^                                                                                                        
  ---------------------------------------------------- ----------------------------------- ------------------- ---------------- -------------------
  Age ≥ 20 yr, n = 33,461,134^†^                                                                                                

  G1, ≥ 90.0                                           63.5 (62.3--64.6)                   2.8 (2.5--3.2)      0.2 (0.2--0.3)   66.5 (65.4--67.6)

  G2, 60.0--89.9                                       28.3 (27.4--29.4)                   2.3 (2.1--2.6)      0.4 (0.3--0.5)   31.0 (30.0--32.1)

  G3a, 45.0--59.9                                      1.3 (1.1--1.5)                      0.5 (0.4--0.6)      0.1 (0.1--0.2)   1.9 (1.7--2.1)

  G3b, 30.0--44.9                                      0.2 (0.1--0.3)                      0.1 (0.1--0.2)      0.1 (0.1--0.1)   0.4 (0.3--0.5)

  G4-5, \< 30.0                                        0.0 (0.0--0.1)                      0.1 (0.0--0.1)      0.1 (0.1--0.2)   0.2 (0.1--0.3)

  Total                                                93.3 (92.8--93.8)                   5.8 (5.3--6.3)      0.9 (0.7--1.1)   100.0

  Age ≥ 60 yr, n = 6,809,154^†^                                                                                                 

  G1, ≥ 90.0                                           21.6 (20.3--23.1)                   2.7 (2.2--3.3)      0.3 (0.1--0.6)   24.6 (23.2--26.1)

  G2, 60.0--89.9                                       56.4 (54.6--58.1)                   7.7 (6.8--8.7)      1.0 (0.7--1.5)   65.1 (63.5--66.6)

  G3a, 45.0--59.9                                      5.9 (5.1--6.8)                      1.9 (1.5--2.4)      0.3 (0.2--0.5)   8.1 (7.2--9.1)

  G3b, 30.0--44.9                                      0.8 (0.6--1.2)                      0.6 (0.4--1.0)      0.2 (0.1--0.5)   1.7 (1.3--2.2)

  G4-5, \< 30.0                                        0.1 (0.0--0.2)                      0.3 (0.1--0.5)      0.2 (0.1--0.3)   0.5 (0.3--0.8)

  Total                                                84.8 (83.4--86.1)                   13.2 (12.0--14.5)   2.0 (1.6--2.5)   100.0

  Diabetes, n = 2,905,239^†^                                                                                                    

  G1, ≥ 90.0                                           37.5 (34.6--40.6)                   6.9 (5.5--8.6)      0.8 (0.4--1.9)   45.2 (42.1--48.3)

  G2, 60.0--89.9                                       34.9 (32.0--37.9)                   8.3 (6.8--9.9)      2.0 (1.3--3.0)   45.1 (42.0--48.3)

  G3a, 45.0--59.9                                      4.4 (3.5--5.7)                      1.8 (1.3--2.7)      0.6 (0.4--1.1)   6.9 (5.7--8.3)

  G3b, 30.0--44.9                                      0.8 (0.4--1.4)                      0.9 (0.5--1.6)      0.2 (0.1--0.7)   1.9 (1.3--2.8)

  G4-5, \< 30.0                                        0.1 (0.0--0.3)                      0.4 (0.2--1.0)      0.4 (0.1--1.1)   0.9 (0.5--1.7)

  Total                                                77.7 (75.2--80.0)                   18.3 (16.2--20.6)   4.0 (3.0--5.5)   100.0

  Hypertension, n = 8,572,299^†^                                                                                                

  G1, ≥ 90.0                                           40.5 (38.7--42.2)                   5.0 (4.2--5.9)      0.6 (0.4--1.0)   46.1 (44.3--47.9)

  G2, 60.0--89.9                                       40.0 (38.2--42.2)                   6.2 (5.4--7.2)      0.9 (0.7--1.3)   47.1 (45.4--48.9)

  G3a, 45.0--59.9                                      3.4 (2.9--4.1)                      1.3 (1.0--1.7)      0.4 (0.2--0.6)   5.1 (4.4--5.8)

  G3b, 30.0--44.9                                      0.6 (0.4--0.8)                      0.3 (0.2--0.5)      0.3 (0.1--0.4)   1.1 (0.9--1.5)

  G4-5, \< 30.0                                        0.0 (0.0--0.2)                      0.2 (0.1--0.4)      0.3 (0.2--0.7)   0.6 (0.4--0.9)

  Total                                                84.5 (83.0--85.8)                   13.0 (11.8--14.4)   2.5 (2.0--3.1)   100.0

  Diagnosed cardiovascular disease, n = 1,045,184^†^                                                                            

  G1, ≥ 90.0                                           27.7 (23.5--32.3)                   2.9 (1.8--4.6)      0.6 (0.2--1.8)   31.1 (26.8--35.8)

  G2, 60.0--89.9                                       44.6 (40.3--49.0)                   6.1 (4.4--8.4)      0.9 (0.4--1.9)   51.6 (47.1--56.0)

  G3a, 45.0--59.9                                      7.1 (5.4--9.4)                      5.3 (3.6--7.8)      0.7 (0.3--1.6)   13.1 (10.5--16.3)

  G3b, 30.0--44.9                                      1.4 (0.7--2.7)                      0.6 (0.2--1.4)      0.6 (0.2--1.9)   2.6 (1.6--4.1)

  G4-5, \< 30.0                                        0.0 (0.0--0.3)                      0.9 (0.3--2.3)      0.6 (0.2--2.9)   1.6 (0.7--3.5)

  Total                                                80.8 (77.2--84.0)                   15.8 (12.9--19.1)   3.4 (2.1--5.5)   100.0
  -------------------------------------------------------------------------------------------------------------------------------------------------

eGFR, estimated glomerular filtration rate; ACR, albumin-to-creatinine ratio.

^\*^Data are presented as the weighted percent estimate (95% confidence interval) for each population; ^†^Numbers are presented as the weighted total number estimate of each population.

Prevalence of CKD by disease stage
----------------------------------

The total prevalence estimate of CKD was 8.2%. By disease stage, the prevalence of CKD was as follows: stage 1, 3.0%; stage 2, 2.7%; stage 3a, 1.9%; stage 3b, 0.4%; and stages 4--5, 0.2% ([Table 2](#T2){ref-type="table"}). The distributions of CKD stages in men were similar to those in women. The prevalence of CKD was higher in older subjects than in younger subjects: 22.0% in the elderly group, 6.4% in the middle-aged group, and 2.8% in the young group. The prevalence of each stage of CKD was higher in the subpopulations with diabetes, hypertension, diagnosed cardiovascular disease, and BMIs of ≥ 30.0 kg/m^2^ and 25.0--29.9 kg/m^2^ than in those without each corresponding characteristic. The prevalence also differed by socioeconomic characteristics, and it was higher in groups with a low education level, low household income, and rural residential area.

###### Prevalence of CKD among adults aged ≥ 20 years by disease stage and selected characteristics: complex samples analysis (Korean National Health and Nutrition Examination Survey, 2011−2013 \[study sample n = 15,319\])
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  Characteristics                    Weighted total number estimate^\*^   Weighted percent estimate (95% confidence interval) of the CKD prevalence                                                                            
  ---------------------------------- ------------------------------------ --------------------------------------------------------------------------- ---------------- ------------------ ------------------- ---------------- -----------------
  Total                              33,461,134                           8.2 (7.6--8.8)                                                              3.0 (2.7--3.4)   2.7 (2.4--3.0)     1.9 (1.7--2.1)      0.4 (0.3--0.5)   0.2 (0.1--0.3)
  Age group, yr                                                                                                                                                                                                                
   ≥ 60                              6,809,154                            22.0 (20.5--23.5)                                                           3.0 (2.4--3.7)   8.7 (7.7--9.8)     8.1 (7.2--9.1)      1.7 (1.3--2.2)   0.5 (0.3--0.8)
   40--59                            14,169,087                           6.4 (5.6--7.2)                                                              3.6 (3.1--4.2)   1.9 (1.6--2.4)     0.5 (0.3--0.8)      0.1 (0.1--0.3)   0.2 (0.1--0.3)
   20--39                            12,482,893                           2.8 (2.3--3.4)                                                              2.4 (1.9--2.9)   0.3 (0.2--0.6)     0.0 (0.0--0.2)      0.0 (0.0--0.1)   0.0 (0.0--0.2)
  Sex                                                                                                                                                                                                                          
   Female                            15,799,793                           8.9 (8.2--9.7)                                                              3.5 (3.0--4.0)   3.0 (2.6--3.4)     1.9 (1.6--2.2)      0.4 (0.3--0.6)   0.2 (0.1--0.4)
   Male                              17,661,341                           7.5 (6.9--8.3)                                                              2.6 (2.2--3.1)   2.5 (2.1--2.9)     1.9 (1.6--2.2)      0.4 (0.3--0.6)   0.13 (0.1--0.2)
  Diabetes                                                                                                                                                                                                                     
   Yes                               2,905,239                            27.6 (25.1--30.3)                                                           7.7 (6.2--9.5)   10.3 (8.7--12.1)   6.9 (5.7--8.4)      1.9 (1.3--2.8)   0.9 (0.5--1.7)
   No                                28,686,661                           6.0 (5.5--6.6)                                                              2.5 (2.2--2.9)   1.9 (1.7--2.2)     1.3 (1.1--1.5)      0.2 (0.2--0.3)   0.1 (0.1--0.2)
  Hypertension                                                                                                                                                                                                                 
   Yes                               8,572,299                            19.6 (18.1--21.1)                                                           5.6 (4.8--6.6)   7.2 (6.3--8.2)     5.1 (4.4--5.8)      1.1 (0.9--1.5)   0.6 (0.4--0.9)
   No                                23,560,793                           6.0 (5.5--6.6)                                                              2.5 (2.2--2.9)   1.9 (1.7--2.2)     1.3 (1.1--1.5)      0.2 (0.2--0.3)   0.1 (0.1--0.2)
  Diagnosed cardiovascular disease                                                                                                                                                                                             
   Yes                               1,045,184                            27.8 (24.0--31.8)                                                           3.5 (2.2--5.4)   7.0 (5.2--9.5)     13.1 (10.5--16.3)   2.6 (1.6--4.1)   1.6 (0.7--3.5)
   No                                31,188,050                           7.5 (6.9--8.0)                                                              3.0 (2.7--3.4)   2.6 (2.3--2.9)     1.5 (1.3--1.7)      0.3 (0.2--0.4)   0.1 (0.1--0.2)
  Body mass index, kg/m^2^                                                                                                                                                                                                     
   ≥ 30.0                            1,557,195                            14.2 (11.3--17.7)                                                           6.5 (4.5--9.1)   5.5 (3.8--7.9)     1.5 (0.8--2.7)      0.4 (0.1--1.0)   0.3 (0.1--2.3)
   25.0--29.9                        9,632,344                            11.1 (10.1--12.2)                                                           3.8 (3.2--4.5)   4.0 (3.4--4.7)     2.5 (2.1--3.0)      0.6 (0.4--0.9)   0.2 (0.1--0.5)
   18.5--24.9                        20,843,849                           6.5 (6.0--7.2)                                                              2.5 (2.1--2.9)   2.0 (1.7--2.3)     1.7 (1.4--2.0)      0.3 (0.2--0.4)   0.1 (0.1--0.2)
   \< 18                             1,371,804                            6.3 (4.5--8.7)                                                              2.7 (1.5--4.9)   1.4 (0.7--2.8)     1.3 (0.7--2.3)      0.4 (0.1--1.3)   0.5 (0.1--1.8)
  Smoker                                                                                                                                                                                                                       
   Yes                               14,200,575                           8.2 (7.4--9.1)                                                              3.0 (2.4--3.6)   2.6 (2.2--3.1)     2.1 (1.8--2.4)      0.4 (0.3--0.6)   0.1 (0.1--0.3)
   No                                18,002,158                           8.0 (7.3--8.8)                                                              3.1 (2.7--3.5)   2.7 (2.4--3.2)     1.6 (1.4--1.9)      0.4 (0.3--0.5)   0.2 (0.1--0.4)

CKD, chronic kidney disease.

^\*^Numbers are presented as the weighted total number estimate of each population.

Prevalence of CKD by risk category
----------------------------------

We grouped eGFR and albuminuria categories with a similar relative risk for CKD outcomes into risk categories ([Table 3](#T3){ref-type="table"}). The proportions of categories with a moderately increased risk, high risk, and very high risk were 6.5%, 1.2%, and 0.5%, respectively. [Fig. 1](#F1){ref-type="fig"} shows the percentages of the moderately increased risk (78.7%), high risk (15.0%), and very high risk (6.2%) categories among the CKD patients. The proportions of the high risk and very high risk categories were increased in subpopulations with older age, diabetes, and cardiovascular disease.

###### Prevalence of CKD among adults aged ≥ 20 years by risk category and selected characteristics: complex samples analysis (Korean National Health and Nutrition Examination Survey, 2011−2013 \[n = 15,319\])
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  Characteristics                    Weighted percent estimate (95% confidence interval)                                       
  ---------------------------------- ----------------------------------------------------- ------------------ ---------------- ---------------
  Total                              91.9 (91.2−92.4)                                      6.4 (6.0−7.0)      1.2 (1.1−1.4)    0.5 (0.4−0.6)
  Age group, yr                                                                                                                
   ≥ 60                              78.1 (76.5−79.5)                                      16.2 (14.9−17.6)   4.1 (3.5−4.8)    1.6 (1.3−2.1)
   40−59                             93.6 (92.9−94.4)                                      5.2 (4.5−5.9)      0.8 (0.6−1.1)    0.4 (0.2−0.6)
   20−39                             97.2 (96.6−97.8)                                      2.6 (2.1−3.1)      0.2 (0.1−0.4)    0.0 (0.0−0.2)
  Sex                                                                                                                          
   Female                            91.0 (90.3−91.8)                                      7.2 (6.5−7.9)      1.2 (1.0−1.5)    0.6 (0.4−0.8)
   Male                              92.4 (91.8−93.1)                                      5.8 (5.2−6.4)      1.3 (1.0−1.6)    0.5 (0.4−0.7)
  Diabetes                                                                                                                     
   Yes                               72.4 (69.7−74.9)                                      19.6 (17.3−22.0)   5.4 (4.2−7.0)    2.6 (1.9−3.7)
   No                                93.9 (93.4−94.5)                                      5.0 (4.5−5.5)      0.8 (0.6−1.0)    0.3 (0.2−0.4)
  Hypertension                                                                                                                 
   Yes                               80.4 (78.9−81.9)                                      14.7 (13.4−16.1)   3.4 (2.8−4.0)    1.5 (1.2−2.0)
   No                                96.1 (95.6−96.5)                                      3.4 (3.0−3.9)      0.4 (0.3−0.6)    0.1 (0.1−0.2)
  Diagnosed cardiovascular disease                                                                                             
   Yes                               72.2 (68.2−76.0)                                      16.2 (13.4−19.4)   8.2 (6.1−10.9)   3.4 (2.1−5.5)
   No                                92.5 (92.0−93.1)                                      6.1 (5.6−6.6)      1.0 (0.8−1.2)    0.4 (0.3−0.5)
  Body mass index, kg/m^2^                                                                                                     
   ≥ 30.0                            85.7 (82.3−88.7)                                      10.9 (8.3−14.1)    2.4 (1.3−4.2)    1.0 (0.4−2.4)
   25.0−29.9                         89.0 (87.8−89.9)                                      8.7 (7.9−9.7)      1.7 (1.4−2.2)    0.6 (0.4−0.9)
   18.5−24.9                         93.4 (92.9−94.0)                                      5.2 (4.7−5.7)      1.0 (0.8−1.2)    0.4 (0.3−0.6)
   \< 18.5                           93.7 (91.3−95.5)                                      4.6 (3.1−6.8)      0.9 (0.4−2.0)    0.8 (0.3−2.1)
  Smoker                                                                                                                       
   Yes                               91.8 (90.9−92.6)                                      6.3 (5.6−7.1)      1.4 (1.1−1.7)    0.5 (0.4−0.7)
   No                                92.0 (91.3−92.7)                                      6.4 (5.8−7.1)      1.1 (0.9−1.3)    0.5 (0.4−0.7)

CKD, chronic kidney disease.

![Proportions of risk categories in various subpopulations with chronic kidney disease.\
DM, diabetes mellitus; HTN, hypertension; CVD, cardiovascular disease; BMI, body mass index.](jkms-31-915-g001){#F1}

Variables associated with the presence of CKD
---------------------------------------------

We evaluated the odds ratios of each variable with or without adjusting for other variables ([Table 4](#T4){ref-type="table"}). In the age-sex adjusted models, the factors of older age, diabetes, hypertension, diagnosed cardiovascular disease, and BMIs of ≥ 30.0 kg/m^2^ and 25.0--29.9 kg/m^2^ were related to the presence of CKD. In fully adjusted models, the factors of older age, diabetes, hypertension, diagnosed cardiovascular disease, BMIs of ≥ 30.0 kg/m^2^, 25.0--29.9 kg/m^2^, and \< 18.5 kg/m^2^, and rural residential area were independently associated with the presence of CKD. The adjusted odds ratios over two-fold were observed in subjects with older age (20-year increment), diabetes, hypertension, and a BMI of ≥ 30 kg/m^2^.

###### Odds ratio for CKD: complex samples analysis (Korean National Health and Nutrition Examination Survey, 2011−2013)

![](jkms-31-915-i004)

  Characteristics^\*^                  Crude odds ratio (95% CI)   Age-sex adjusted odds ratio (95% CI)   Fully adjusted odds ratio^†^ (95% CI)
  ------------------------------------ --------------------------- -------------------------------------- ---------------------------------------
  Age, 20-year increment               3.6 (3.2--3.9)              3.6 (3.2--3.9)                         2.4 (2.1--2.8)
  Female sex                           1.2 (1.1--1.4)              1.0 (0.9--1.1)                         1.2 (0.9--1.5)
  Diabetes                             6.0 (5.1--7.0)              3.4 (2.8--4.0)                         2.7 (2.2--3.2)
  Hypertension                         5.9 (5.1--6.8)              3.2 (2.7--3.7)                         2.5 (2.1--3.0)
  Diagnosed cardiovascular disease     4.8 (3.9--5.9)              2.0 (1.6--2.5)                         1.6 (1.3--2.0)
  Body mass index^‡^, kg/m^2^                                                                             
   ≥ 30.0                              2.4 (1.8--3.1)              3.4 (2.5--4.6)                         2.1 (1.5--3.0)
   25.0--29.9                          1.8 (1.6--2.0)              1.8 (1.5--2.0)                         1.4 (1.2--1.7)
   \< 18.5                             1.0 (0.7--1.4)              1.3 (0.9--2.0)                         1.6 (1.0--2.5)
  Smoker                               1.0 (0.9--1.2)              1.2 (0.9--1.5)                         1.1 (0.9--1.4)
  Education, \< high school graduate   3.5 (3.1--4.0)              1.1 (1.0--1.4)                         0.9 (0.8--1.1)
  Household income, lower 1/4          2.9 (2.5--3.3)              1.2 (1.0--1.3)                         1.1 (0.9--1.3)
  Residential area, rural              1.7 (1.4--2.0)              1.2 (1.0--1.4)                         1.3 (1.0--1.5)

CKD, chronic kidney disease; CI, confidence interval.

^\*^The group without each corresponding characteristics served as the reference; ^†^The odds ratio was adjusted for all other variables, and the variables included in the model were age, sex, diabetes, hypertension, cardiovascular disease, body mass index category, smoking, education, income, and residence; ^‡^The group with a body mass index of 18.5−24.9 kg/m^2^ served as the reference.

DISCUSSION
==========

In this population-based study, albuminuria with an ACR ≥ 30 mg/g and a decreased GFR with an eGFR \< 60 mL/min/1.73 m^2^ were observed in 6.7% and 2.5%, respectively, of the Korean population aged ≥ 20 years. The total prevalence estimate of CKD for adults aged ≥ 20 years in Korea was 8.2% when CKD was defined as an ACR ≥ 30 mg/g or an eGFR \< 60 mL/min/1.73 m^2^. By disease stage, the prevalence was as follows: stage 1, 3.0%; stage 2, 2.7%; stage 3A, 1.9%; stage 3B, 0.4%; and stages 4/5, 0.2%. By risk category, the prevalence was as follows: moderate risk, 6.5%; high risk, 1.2%; and very high risk, 0.5%.

The prevalence of CKD worldwide has been reported as approximately 10%--14% in studies conducted in various countries. The prevalence of CKD was 13.1% among adults aged ≥ 20 years in the United States ([@B7]), 10.2% of adults aged ≥ 20 years in Norway ([@B12]), 13.2% of persons aged ≥ 40 years in northeastern Italy ([@B13]), 12.5% of adults aged ≥ 18 years in Canada ([@B14]), 10.8% of adults aged ≥ 18 years in China ([@B8]), 13.2% of adults aged ≥ 20 years in Japan ([@B15]), and 13.7% of persons aged ≥ 35 years in Korea ([@B9]). These prevalence estimates of CKD may be influenced by the study sampling design, serum creatinine and urine albumin assays, calculation formula of eGFR, and definition/classification of CKD.

In the present study, the eGFR was calculated from the serum creatinine level standardized to IDMS using the CKD-EPI creatinine equation. The CKD-EPI creatinine equation more accurately estimates GFR ([@B11]) and more accurately categorizes the risk of death than the MDRD equation ([@B1]). The accuracy of the equation has also been previously demonstrated in Asian populations, including Koreans ([@B16],[@B17]). Proper use of GFR estimating equations requires an equation-specific calibration of the serum creatinine assays ([@B18],[@B19]). Due to the variability between calibration methods, assays not calibrated to IDMS introduce a source of error into GFR estimates.

Furthermore, a standard study design for a population and a design-consistent estimation are required to obtain unbiased estimates. KNHANES is a nationwide, population-based study that used a stratified, multistage, clustered probability design, whereas we estimated the prevalence with a design-consistent method that incorporated the sample weight, stratum, and primary sampling unit.

A previous study, which reported the prevalence of CKD in the Korean population as 13.7% in adults aged ≥ 35 years, also measured urine ACR and made a diagnosis of CKD using a similar criteria to ours ([@B9]). However, the subjects were included only from urban areas and the sample size was not sufficiently large to reliably represent the entire Korean population. Moreover, the serum creatinine level was not standardized to IDMS and the eGFR was calculated using the MDRD equation rather than the CKD-EPI equation. When we recalculated the eGFR in our study population using the MDRD equation, the prevalence of CKD with an eGFR \< 60 mL/min/1.73 m^2^ or an ACR ≥ 30 mg/g was estimated as 8.8% in the Korean population aged ≥ 20 years and 11.3% in the population aged ≥ 35 years.

Previous studies analyzing the KNHANES data have reported higher prevalence rates of stages 3 and 4 CKD with an eGFR \< 60 mL/min/1.73 m^2^ than our estimates ([@B20]--[@B22]). However, the differences between our estimates and previously published prevalence estimates should not be interpreted as representing time trends. Because creatinine levels were not standardized to IDMS in the KNHANES before 2008, the eGFRs were calculated using the MDRD equation. Moreover, most of the previous studies calculated the prevalence rates without incorporation of the sample weights. The higher prevalence estimates of CKD in those studies could therefore be explained by the following reasons. First, non-standardized creatinine levels are usually higher than IDMS-standardized levels ([@B23]). When we compared the levels within the KNHANES 2008 data, which included both the non-standardized/standardized levels, the non-standardized serum levels (mean ± SE, 0.94 ± 0.004 mg/dL) were substantially higher than those standardized to IDMS (mean ± SE, 0.82 ± 0.005 mg/dL) in people with ages (mean ± SE) of 49.6 ± 0.31 years and 49.1 ± 0.27 years, respectively. Furthermore, on condition that serum creatinine levels are equal, the MDRD equation may classify more persons into CKD compared to the CKD-EPI equation ([@B1]). Finally, the unweighted analysis of the KNHANES, in which older people participated relatively more, can overestimate the prevalence. When we re-estimated the prevalence in our study population without incorporation of the sample weight, 10.5% rather than 8.2% of adults aged ≥ 20 years had CKD. Additionally, the KNHANES data analyzed by previous studies did not include information on the ACR because urine ACR has been measured in the KNHANES since 2011.

To evaluate the differences of the prevalence estimates within the whole KNHANES data, we computed the prevalence estimates from 1998 to 2013. [Fig. 2A](#F2){ref-type="fig"} and [2B](#F2){ref-type="fig"} shows yearly differences of the prevalence estimates from 2009; since that year, serum creatinine levels have been standardized to IDMS in the KNHANES. The prevalence of CKD with an eGFR \< 60 mL/min/1.73 m^2^ has not been decreasing in recent years. The prevalence estimates of CKD from 1998 to 2007, during which creatinine levels were not standardized, are also shown in [Fig. 2C](#F2){ref-type="fig"} and [2D](#F2){ref-type="fig"}. There were rapid changes in the prevalence estimates during that period.

![Differences in the prevalence estimates of chronic kidney disease within the entire KNHANES data set. (**A**) CKD with an eGFR ≤ 60 mL/min/1.73 m^2^ using both the CPK-EPI and MDRD equations, from 2009 to 2013. (**B**) CKD with dipstick-positive proteinuria ≥ 1+ or an eGFR ≤ 60 mL/min/1.73 m^2^ using both the CPK-EPI and MDRD equations, from 2009 to 2013. (**C**) CKD with an eGFR ≤ 60 mL/min/1.73 m^2^ using the MDRD equation, from 1998 to 2007. (**D**) CKD with or dipstick-positivie proteinuria ≥ 1+ or an eGFR ≤60 mL/min/1.73 m^2^ using the MDRD equation, from 1998 to 2007.\
KNHANES, Korean National Health and Nutrition Examination Survey; eGFR, estimated glomerula filtration rate; CPK-EPI, Chronic Kidney Disease-Epidemiology Collaboration; MDRD, Modification of Diet in Renal Disease Study.](jkms-31-915-g002){#F2}

Most studies that have been reported until now classified CKD principally by eGFR category. However, albuminuria itself is recognized as a risk factor for end-stage renal disease and cardiovascular events ([@B24],[@B25]). In CKD with a normal or mildly decreased eGFR, albuminuria is more predictive of adverse kidney outcomes and all-cause/cardiovascular mortality than the eGFR ([@B26]--[@B28]). This has prompted the need for new risk stratification for adverse outcomes based on both the eGFR and albuminuria. The 2012 KDIGO guidelines recommend that CKD be classified based on cause, the GFR category, and the albuminuria category. According to the recommendation, we assigned subjects to an albuminuria category as well as an eGFR category. Furthermore, we grouped the eGFR and albuminuria categories with a similar relative risk for adverse outcomes into three risk categories: moderately increased risk, high risk, and very high risk ([@B10]).

In the present study, a high BMI of ≥ 25.0 kg/m^2^ was an independent predictor of CKD ([Table 4](#T4){ref-type="table"}). Previous longitudinal studies, performed in the United States ([@B29]) and Thailand ([@B30]) have demonstrated that a high BMI is an independent risk factor for the development of new-onset kidney dysfunction with an eGFR \< 60 mL/min/1.73 m^2^. These results suggest that weight reduction in obese persons is helpful to prevent the development or progression of CKD. However, our study also showed that the lowest BMI of \< 18.5 kg/m^2^ was associated with the presence of CKD after adjusting for other variables. However, a causal relationship between the lowest BMI and CKD cannot be argued from our cross-sectional study because CKD may cause malnutrition and weight loss. In addition to BMI, well-known risk factors such as older age, hypertension, diabetes, and cardiovascular disease were also associated with an increased risk of CKD.

The CKD prevalence in Korea (8.2%) shown in our study was somewhat lower than those of the United States (10.0% and 13.1%) ([@B7]) and China (10.8%) ([@B8]) ([Table 5](#T5){ref-type="table"}). Stages 3 and 4 CKD with an eGFR \< 60 mL/min/1.73 m^2^ were more prevalent in the United States, whereas stages 1 and 2 CKD with an ACR ≥ 30 mg/g were more prevalent in the Korean and Chinese population. Among the associated factors for CKD, the BMI of the Korean population was lower than the United States population. This relatively lower BMI may at least partially account for the lower prevalence of CKD in Korea. Diabetes was less prevalent in the United States, but this may be owing to the difference in the definition of diabetes between studies (i.e., self-reported diabetes in data from the United States vs. the laboratory examinations-based diagnosis in our study) rather than a reflection of the true prevalence of diabetes. In a recent report, approximately 1 in 4 persons with diabetes was unaware that he/she had diabetes ([@B31]). Chinese data showed a relatively higher mean age and higher prevalence of hypertension.

###### Comparison of baseline characteristics and CKD prevalence according to nationwide studies in Korea, China, and the United States
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  Characteristics                       Korea^\*^   China   United States   
  ------------------------------------- ----------- ------- --------------- ------
  Age (mean), yr                        46.1        49.6    44.8            46.2
  Female sex, %                         47.2        57.3    52.2            51.8
  eGFR (mean), mL/min/1.73 m^2^         95.9        101.2   92.7            87.4
  ACR (mean), mg/g                      18.3        6.6     25.4            28.6
  ACR \> 30 mg/g, %                     6.7         9.4     8.2             9.5
  Diabetes mellitus, %                  9.2         7.4     5.4             6.8
  Hypertension, %                       26.7        35.4    23.8            27.1
  Diagnosed cardiovascular disease, %   3.2         2.6     N/A             N/A
  Body mass index (mean), kg/m^2^       23.9        23.9    26.6            28.1
  CKD stage, %                                                              
   Total                                8.2         10.8    10.0            13.1
   1                                    3.0         5.7     1.7             1.8
   2                                    2.7         3.4     2.7             3.2
   3a                                   1.9         1.4     5.4             7.7
   3b                                   0.4         0.2                     
   4                                    0.2         0.1     0.2             0.4
   5                                    0.03        N/A     N/A             

eGFR, estimated glomerular filtration rate; ACR, albumin creatinine ratio; CKD, chronic kidney disease; N/A, not applicable.

^\*^Data are presented as the weighted percent or mean estimate.

There are some limitations to our study. First, we estimated GFR using a serum creatinine-based equation rather than directly measuring it using an exogenous ideal marker of GFR. The potential difference between the measured and estimated GFR may be influenced by the population in which the equation is applied. Such a bias may contribute to racial/ethnic differences in prevalence estimates. Second, the serum creatinine for each person was measured only once. A single eGFR value cannot precisely reflect kidney function, and there exists the possibility that patients with acute kidney injury were included. Likewise, urine albumin was measured only once; thus, transient albuminuria could not be excluded. Finally, there is a potential difference in the survey response rate, which may be lower among sicker individuals and bias the present prevalence estimates. Thus, the prevalence of stages 4 and 5 CKD would have been underestimated in KNHANES, which enrolled non-institutionalized individuals who volunteered to participate.

In conclusion, the prevalence of CKD among adults aged ≥ 20 years was 8.2% in this nationwide representative sample of the Korean population. Albuminuria with an ACR ≥ 30 mg/g was observed in 6.7%, whereas a decreased GFR with an eGFR \< 60 mL/min/1.73 m^2^ was observed in 2.5% of the population. Factors such as older age, diabetes, hypertension, cardiovascular disease, and high BMI are associated with the presence of CKD. Evidence-based, customized screening strategies for CKD in the Korean population are needed to optimize prevention and early intervention of CKD, and its associated risk factors.
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